18 March 2025
In this issue Insights from our Executive Director Reflecting on our journey from 2017—when NZBIO faced financial challenges and joined the NZTech Group—to today is truly remarkable. Four years of … Continue reading "Merck Expands Celonic’s Upstream Capabilities with Mobius(R) Single-use Bioreactors"
Read More
12 February 2025
In this issue Insights from our Executive Director As we kick off the year, BioTechNZ is already moving full speed ahead with exciting developments in the biotech sector. There is … Continue reading "Merck Expands Celonic’s Upstream Capabilities with Mobius(R) Single-use Bioreactors"
Read More
16 December 2024
It has been a landmark year for BioTechNZ and our members. Let's take a moment to reflect on the progress and achievements of 2024!
Read More
30 September 2024
Kia ora, In this issue Insights from our Executive Director The more I work in this role the more excited I am about the convergence of once-siloed technologies across multidisciplinary … Continue reading "Merck Expands Celonic’s Upstream Capabilities with Mobius(R) Single-use Bioreactors"
Read More
03 September 2024
In this issue Insights from our Executive Director During the last month there has been plenty of discussion in the media regarding gene technologies – should our companies and researchers … Continue reading "Merck Expands Celonic’s Upstream Capabilities with Mobius(R) Single-use Bioreactors"
Read More
02 September 2024
We can’t wait to reconnect at Aotearoa New Zealand’s 2025 Life Science Summit – Uniting biology and technology to unleash potential. 18-19 March, 2025 at Tākina Wellington Convention and Exhibition Centre. Click here … Continue reading "Merck Expands Celonic’s Upstream Capabilities with Mobius(R) Single-use Bioreactors"
Read More
21 June 2024
It has been another busy month for biotech. More than 35 Kiwis travelled to the BIO International Convention in San Diego.
Read More
06 March 2024
In this issue Insights from our Executive Director This year feels like it’s going to be a fast game, but a good game for the biotech sector! I am incredibly … Continue reading "Merck Expands Celonic’s Upstream Capabilities with Mobius(R) Single-use Bioreactors"
Read More
Merck, a leading science and technology company, today announced that Celonic AG, a Swiss contract development and manufacturing organization (CDMO), is upgrading its manufacturing facility with five of Merck's Mobius(R) single-use bioreactors. Celonic, which produces biosimilars and also offers
September 13, 2017
A National Government will partner with farmers and growers to develop new farming technology and practices that lift productivity and further reduce farming’s environmental footprint, Primary Industries spokesperson Nathan Guy says. “National will turbo-charge the Sustainable Farming Fund, w
September 12, 2017
A tech company that helps farmers improve crop yields will list on the Australian Securities Exchange on Tuesday. CropLogic has raised the $8 million it sought in an IPO, and said it was even offered $1 million on top of that during the offer period. Forty million ordinary shares will be issued a
September 12, 2017
Kiwi agtech play CropLogic’s ASX debut disappointed investors, finishing its first day down 23 per cent from its IPO price at 15.5c. The company, which offers crop management technology-as-a-service focused, for now, on potato crops, raised its target $8 million during the IPO, selling 40 milli
September 12, 2017
Australian life sciences investment firm BioScience Managers has chosen a robotic exercise assist device (REX) as its first investment for the Biomedical Translation Fund. The REX Bionics robotic device has been in development for over a decade and has racked up thousands of hours of user experie
September 12, 2017
Tru-Test Corp has hired Simon Mander to lead the agritech company as it looks to build earnings after a hard round of cost-cutting in response to last year’s dairy downturn. Mander started at the Auckland-based company today, replacing Greg Muir who stepped down after more than eight years in t
September 11, 2017
Twenty years ago this week, husband and wife Dr Hartley Atkinson and Marree Atkinson, started AFT Pharmaceuticals (AFT) in a room off their home garage. Last year the NZX and ASX listed company earned revenue of NZ$70M and has a market capitalisation of around NZ$250M. Reflecting on 20 years in
August 31, 2017
Upside Biotechnologies appoints leading US life sciences executive to Board Regenerative medicine start-up, Upside Biotechnologies, has appointed Boston-based Dr Daniel R. Marshak Ph.D. to its Board. New Zealand-based Upside is developing an advanced, world-class skin replacement treatment for p
August 23, 2017
The New Zealand Government announced an investment of up to NZ$35 million over seven years in Genomics Aotearoa (GA), a new collaborative science organisation supporting advanced genomics research. Genomics Aotearoa is an alliance led by the University of Otago and includes the Universities
August 21, 2017